Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells

详细信息	查看全文 | 推荐本文 |

• 作者：Adnan O. Abu-Yousif⁵ ; Anne C.E. Moor¹ ; ⁵ ; Xiang Zheng ; Mark D. Savellano² ; Weiping Yu³ ; På ; l K. Selbo⁴ ; Tayyaba Hasan ; ^{thasan@partners.org}
• 关键词：Ovarian cancer ; Photodynamic therapy ; Cetuximab ; Verteporfin ; Immunoconjugate
• 刊名：Cancer Letters
• 出版年：2012
• 期刊代码：44_03043835
• 类别：med
• 出版时间：28 August, 2012
• 卷：321
• 期：2
• 页码：120-127
• 文件大小：1012 K

摘要

Targeted photosensitizer delivery to EGFR-expressing cells was achieved in the present study using a high purity, targeted photoimmunoconjugate (PIC). When the PDT agent, benzoporphyrin derivative monoacid ring A (BPD) was coupled to an EGFR-targeting antibody (cetuximab), we observed altered cellular localization and selective phototoxicity of EGFR-positive cells, but no phototoxicity of EGFR-negative cells. Cetuximab in the PIC formulation blocked EGF-induced activation of the EGFR and downstream signaling pathways. Our results suggest that photoimmunotargeting is a useful dual strategy for the selective destruction of cancer cells and also exerts the receptor-blocking biological function of the antibody.